ArticleAntioxidants (Basel, Switzerland)2023

CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease.

James Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.